Search

Your search keyword '"Kuo, Chi-Tai"' showing total 8 results
Start Over Author "Kuo, Chi-Tai" Database OpenAIRE
8 results on '"Kuo, Chi-Tai"'

1. Oral Anticoagulant Use for Patients with Atrial Fibrillation with Concomitant Anemia and/or Thrombocytopenia

Author

Yeh, Yung-Hsin, Chan, Yi-Hsin, Chen, Shao-Wei, Chang, Shang-Hung, Wang, Chun-Li, Kuo, Chi-Tai, Lip, Gregory Y. H., Chen, Shih-Ann, and Chao, Tze-Fan

Subjects
Embolism, Administration, Oral, Warfarin/therapeutic use, Hemorrhage, Hemorrhage/epidemiology, Hemoglobins, Embolism/complications, Risk Factors, Atrial Fibrillation, Humans, NOACs, Hemoglobin, Ischemic Stroke, Thrombocytopenia/chemically induced, Platelet, Anticoagulants, Anemia, General Medicine, Atrial fibrillation, Thrombocytopenia, Stroke, Anticoagulants/therapeutic use, Intracranial Hemorrhages/chemically induced, Anemia/complications, Warfarin, Intracranial Hemorrhages, Stroke/drug therapy, Atrial Fibrillation/complications
Abstract

OBJECTIVE: Hemoglobin levels and platelet counts have been associated with adverse clinical outcomes in patients with cardiovascular conditions. We aimed to assess the impact of oral anticoagulant use for patients with atrial fibrillation and concomitant anemia or thrombocytopenia.METHODS: We used medical data from a multicenter health care system in Taiwan including 37,074 patients with atrial fibrillation. Patients were categorized into 3 groups based on hemoglobin and platelet levels: Group 1 (hemoglobin >10g/dL and platelet>100 K/µL; n = 29,147), Group 2 (hemoglobinRESULTS: A higher hemoglobin or platelet level was associated with a higher risk of ischemic stroke/systemic embolism but lower risks of intracranial hemorrhage and major bleeding. The composite risks of ischemic stroke/systemic embolism, intracranial hemorrhage and major bleeding were higher in Group 3 or Group 2, compared with Group 1 (6.79% a year vs 6.41% year vs 4.13% year). Compared to non-OACs, warfarin was not associated with a lower composite risk in the 3 groups. NOACs were associated with a lower composite risk in Group 1 (adjusted hazard ratio:0.68, [95% confidence interval:0.60-0.76]) and Group 2 (adjusted hazard ratio:0.73, [95% confidence interval:0.53-0.99]) but was nonsignificant in Group 3.CONCLUSIONS: Patients with atrial fibrillation with anemia or thrombocytopenia were a high-risk population. Compared with no OAC use, NOACs were associated with better clinical outcomes for patients with atrial fibrillation and advanced anemia (hemoglobin

Published
2022

2. Additional file 1 of The risk of incident atrial fibrillation in patients with type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors: a nationwide cohort study

Author

Chan, Yi-Hsin, Chao, Tze-Fan, Chen, Shao-Wei, Lee, Hsin-Fu, Li, Pei-Ru, Chen, Wei-Min, Yeh, Yung-Hsin, Kuo, Chi-Tai, See, Lai-Chu, and Lip, Gregory Y. H.

Abstract

Additional file 1: Table S1 International Classification of Diseases (10th edition) Clinical Modification (ICD 10-CM) codes used to define comorbidities and clinical outcomes in this study.

Published
2022
Full Text
View/download PDF

3. Metformin is associated with fewer major adverse cardiac events among patients with a new diagnosis of type 2 diabetes mellitus

Author

Lee, Kuang-Tso, Yeh, Yung-Hsin, Chang, Shang-Hung, See, Lai-Chu, Lee, Cheng-Hung, Wu, Lung-Sheng, Liu, Jia-Rou, Kuo, Chi-Tai, and Wen, Ming-Shien

Subjects
Adult, Male, Adolescent, Databases, Factual, Heart Diseases, Incidence, Taiwan, Observational Study, Comorbidity, Middle Aged, Metformin, Young Adult, Diabetes Mellitus, Type 2, diabetes mellitus, Humans, Hypoglycemic Agents, Female, Longitudinal Studies, Propensity Score, major adverse cardiac events, Research Article, Follow-Up Studies, Aged, Proportional Hazards Models
Abstract

Early type 2 diabetes mellitus (DM) may only require lifestyle modifications for glycemic control without the need for oral hypoglycemic agents (OHAs). Metformin is believed to improve cardiovascular outcomes in patients with DM, and it is considered to be a first-line therapy. However, it is unclear whether metformin is beneficial for patients with a new diagnosis of DM compared to those who do not need OHAs for glycemic control. Data were obtained from a population-based health care database in Taiwan. Patients with a new diagnosis of DM were enrolled if they received metformin monotherapy only between 1999 and 2010. A 4:1 propensity score-matched cohort of patients with a new diagnosis of DM who did not take OHAs or insulin during follow-up was also enrolled. The primary study endpoint was the occurrence of major adverse cardiovascular events (MACEs). The time to the endpoints was compared between groups using Cox proportional hazards models. A total of 474,410 patients with DM were enrolled. During a mean 5.8 years of follow-up, the incidence of MACEs was 1.072% (1072 per 100,000 person-years) in the metformin monotherapy group versus 1.165% in the lifestyle modification group (those who did not take OHAs) (P

Published
2017

4. Effect of aliskiren on post-discharge outcomes among diabetic and non-diabetic patients hospitalized for heart failure: insights from the ASTRONAUT trial

Author

Maggioni, Aldo P., Greene, Stephen J., Fonarow, Gregg C., Böhm, Michael, Zannad, Faiez, Solomon, Scott D., Lewis, Eldrin F., Baschiera, Fabio, Hua, Tsushung A., Gimpelewicz, Claudio R., Lesogor, Anastasia, Gheorghiade, Mihai, Ramos, Silvina, Luna, Alejandra, Miriuka, Santiago, Diez, Mirta, Perna, Eduardo, Luquez, Hugo, Pinna, Jorge Garcia, Castagnino, Jorge, Alvarenga, Pablo, Ibañez, Julio, Blumberg, Eduardo Salmon, Dizeo, Claudio, Guerrero, Rodolfo Ahuad, Schygiel, Pablo, Milesi, Rodolfo, Sosa, Carlos, Hominal, Miguel, Marquez, Lilia Lobo, Poy, Carlos, Hasbani, Eduardo, Vico, Marisa, Fernandez, Alberto, Vita, Nestor, Vanhaecke, Johan, De Keulenaer, Gilles, Striekwold, Harry, Vervoort, Geert, Vrolix, Mathias, Henry, Philippe, Dendale, Paul, Smolders, Walter, Marechal, Patrick, Vandekerckhove, Hans, Oliveira, Mucio, Neuenschwande, Fernando, Reis, Gilmar, Saraiva, Jose, Bodanese, Luiz, Canesin, Manoel, Greco, Oswaldo, Bassan, Roberto, Marino, Roberto Luis, Giannetti, Nadia, Moe, Gordon, Sussex, Bruce, Sheppard, Richard, Huynh, Thao, Stewart, Robert, Haddad, Haissam, Echeverria, Luis, Quintero, Adalberto, Torres, Adriana, Jaramillo, Mónica, Lopez, Mónica, Mendoza, Fernan, Florez, Noel, Cotes, Carlos, Garcia, Magali, Belohlavek, Jan, Hradec, Jaromir, Peterka, Martin, Gregor, Pavel, Monhart, Zdenek, Jansky, Petr, Kettner, Jiri, Reichert, Petr, Spinar, Jindrich, Brabec, Tomas, Hutyra, Martin, Solar, Miroslav, Pietilä, Mikko, Nyman, Kai, Pajari, Risto, Cohen, Ariel, Galinier, Michel, Gosse, Philippe, Livarek, Bernard, Neuder, Yannick, Jourdain, Patrick, Picard, François, Isnard, Richard, Hoppe, Uta, Kaeaeb, Stefan, Rosocha, Stefan, Prondzinsky, Roland, Felix, Stephan, Duengen, Hans-Dirk, Figulla, Hans-Reiner, Fischer, Sven, Behrens, Steffen, Stawowy, Philipp, Kruells-Muench, Juergen, Knebel, Fabian, Nienaber, Christoph, Werner, Dierk, Aron, Wilma, Remppis, Bjoern, Hambrecht, Rainer, Kisters, Klaus, Werner, Nikos, Hoffmann, Stefan, Rossol, Siegbert, Geiss, Ernst, Graf, Kristof, Hamann, Frank, von Scheidt, Wolfgang, Schwinger, Robert, Tebbe, Ulrich, Costard-Jaeckle, Angelika, Lueders, Stephan, Heitzer, Thomas, Leutermann-Oei, Marie-Louise, Braun-Dullaeus, Ruediger, Roehnisch, Jens-Uwe, Muth, Gerhard, Goette, Andreas, Rotter, Achim, Ebelt, Henning, Olbrich, Hans-Georg, Mitrovic, Veselin, Hengstenberg, Christian, Schellong, Sebastian, Zamolyi, Karoly, Vertes, Andras, Matoltsy, Andras, Palinkas, Attila, Herczeg, Bela, Apro, Dezso, Lupkovics, Geza, Tomcsanyi, Janos, Toth, Kalman, Mathur, Atul, Banker, Darshan, Bharani, Anil, Arneja, Jaspal, Khan, Aziz, Gadkari, Milind, Hiremath, Jagdish, Patki, Nitin, Kumbla, Makund, Santosh, M.J., Ravikishore, A.G., Abhaichand, Rajpal, Maniyal, Vijayakukmar, Nanjappa, Manjunath, Reddy, P. Naveen, Chockalingam, Kulasekaran, Premchand, Rajendra, Mahajan, Vijay, Lewis, Basil, Wexler, Dov, Shochat, Michael, Keren, Andre, Omary, Muhamad, Katz, Amos, Marmor, Alon, Lembo, Giuseppe, Di Somma, Salvatore, Boccanelli, Alessandro, Barbiero, Mario, Pajes, Giuseppe, De Servi, Stefano, Greco, Dott Cosimo, De Santis, Fernando, Floresta, Agata, Visconti, Luigi Oltrona, Piovaccari, Giancarlo, Cavallini, Claudio, Di Biase, Matteo, Masini, Dott Franco, Vassanelli, Corrado, Viecca, Maurizio, Cangemi, Dott Francesco, Pirelli, Salvatore, Borghi, Claudio, Volpe, Massimo, Branzi, Angelo, Percoco, Dott Giovanni, Severi, Silvia, Santini, Alberto, De Lorenzi, Ettore, Metra, Marco, Zacà, Valerio, Mortara, Andrea, Tranquilino, Francisco P., Babilonia, Noe A., Ferrolino, Arthur M., Manlutac, Benjamin, Dluzniewski, Miroslaw, Dzielinska, Zofia, Nowalany-Kozie, Ewa, Mazurek, Walentyna, Wierzchowiecki, Jerzy, Wysokinski, Andrzej, Szachniewicz, Joanna, Romanowski, Witold, Krauze-Wielicka, Magdalena, Jankowski, Piotr, Berkowski, Piotr, Szelemej, Roman, Kleinrok, Andrzej, Kornacewicz-Jac, Zdzislawa, Vintila, Marius, Vladoianu, Mircea, Militaru, Constantin, Dan, Gheorghe, Dorobantu, Maria, Dragulescu, Stefan, Kostenko, Victor, Vishnevsky, Alexandr, Goloschekin, Boris, Tyrenko, Vadim, Gordienko, Alexander, Kislyak, Oxana, Martsevich, Sergey, Kuchmin, Alexey, Karpov, Yurii, Fomin, Igor, Shvarts, Yury, Orlikova, Olga, Ershova, Olga, Berkovich, Olga, Sitnikova, Maria, Pakhomova, Inna, Boldueva, Svetlana, Tyurina, Tatiana, Simanenkov, Vladimir, Boyarkin, Mikhail, Novikova, Nina, Tereschenko, Sergey, Zadionchenko, Vladimir, Shogenov, Zaur, Gordeev, Ivan, Moiseev, Valentin, Wong, Raymond, Ong, Hean Yee, Le Tan, Ju, Goncalvesova, Eva, Kovar, Frantisek, Skalina, Ivan, Kasperova, Viera, Hojerova, Silvia, Szentivanyi, Miroslav, Stancak, Branislav, Babcak, Marian, Kycina, Peter, Poliacik, Pavol, Toth, Peter, Sirotiakova, Jana, de Sa, Esteban Lopez, Bueno, Manuel Gomez, Selles, Manuel Martinez, Cabrera, Jose Angel, Freire, Ramon Bover, Gonzalez Juanatey, Jose Ramon, Comin, Josep, Soriano, FranciscoRidocci, Lopez, Alejandro, Vicho, Raul, Lama, Manuel Geraldia, Schaufelberger, Maria, Brunotte, Richard, Ullman, Bengt, Hagerman, Inger, Cizinsky, Stella, Cherng, Wen-Jin, Yu, Wen-Chung, Kuo, Chi-Tai, Chang, Kuan-Cheng, Lai, Wen-Ter, Kuo, Jen-Yuan, Ural, Dilek, Badak, Ozer, Akin, Mustafa, Yigit, Zerrin, Yokusoglu, Mehmet, Yilmaz, Mehmet, Abaci, Adnan, Ebinc, Haksun, Perlman, Richard, Parish, David, Bergin, James, Burnham, Kenneth, Brown, Christopher, Lundbye, Justin, Williams, Celeste, Eisen, Howard, Juneman, Elizabeth, Joseph, Susan, Peberdy, Mary Ann, Peura, Jennifer, Gupta, Vishal, Habet, Kalim, French, William, Mody, Freny, Graham, Susan, Hazelrigg, Monica, Chung, Eugene, Dunlap, Stephanie, Nikolaidis, Lazaros, Najjar, Samer, Katz, Richard, Murali, Srinivas, Izzo, Joseph L., Callister, Tracy, Phillips, Roland, Lippolis, Nicholas, Winterton, John, Meymandi, Sheba, Heilman, Karl, Oren, Ron, Zolty, Ronald, Brottman, Michael, Gunawardena, D.R., Adams, Kirkwood, Barnard, Denise, Klapholz, Marc, Fulmer, James, Maggioni AP, Greene SJ, Fonarow GC, Böhm M, Zannad F, Solomon SD, Lewis EF, Baschiera F, Hua TA, Gimpelewicz CR, Lesogor A, Gheorghiade M, Ramos S, Luna A, Miriuka S, Diez M, Perna E, Luquez H, Pinna JG, Castagnino J, Alvarenga P, Ibañez J, Blumberg ES, Dizeo C, Guerrero RA, Schygiel P, Milesi R, Sosa C, Hominal M, Marquez LL, Poy C, Hasbani E, Vico M, Fernandez A, Vita N, Vanhaecke J, De Keulenaer G, Striekwold H, Vervoort G, Vrolix M, Henry P, Dendale P, Smolders W, Marechal P, Vandekerckhove H, Oliveira M, Neuenschwande F, Reis G, Saraiva J, Bodanese L, Canesin M, Greco O, Bassan R, Marino RL, Giannetti N, Moe G, Sussex B, Sheppard R, Huynh T, Stewart R, Haddad H, Echeverria L, Quintero A, Torres A, Jaramillo M, Lopez M, Mendoza F, Florez N, Cotes C, Garcia M, Belohlavek J, Hradec J, Peterka M, Gregor P, Monhart Z, Jansky P, Kettner J, Reichert P, Spinar J, Brabec T, Hutyra M, Solar M, Pietilä M, Nyman K, Pajari R, Cohen A, Galinier M, Gosse P, Livarek B, Neuder Y, Jourdain P, Picard F, Isnard R, Hoppe U, Kaeaeb S, Rosocha S, Prondzinsky R, Felix S, Duengen HD, Figulla HR, Fischer S, Behrens S, Stawowy P, Kruells-Muench J, Knebel F, Nienaber C, Werner D, Aron W, Remppis B, Hambrecht R, Kisters K, Werner N, Hoffmann S, Rossol S, Geiss E, Graf K, Hamann F, von Scheidt W, Schwinger R, Tebbe U, Costard-Jaeckle A, Lueders S, Heitzer T, Leutermann-Oei ML, Braun-Dullaeus R, Roehnisch JU, Muth G, Goette A, Rotter A, Ebelt H, Olbrich HG, Mitrovic V, Hengstenberg C, Schellong S, Zamolyi K, Vertes A, Matoltsy A, Palinkas A, Herczeg B, Apro D, Lupkovics G, Tomcsanyi J, Toth K, Mathur A, Banker D, Bharani A, Arneja J, Khan A, Gadkari M, Hiremath J, Patki N, Kumbla M, Santosh MJ, Ravikishore AG, Abhaichand R, Maniyal V, Nanjappa M, Reddy PN, Chockalingam K, Premchand R, Mahajan V, Lewis B, Wexler D, Shochat M, Keren A, Omary M, Katz A, Marmor A, Lembo G, Di Somma S, Boccanelli A, Barbiero M, Pajes G, De Servi S, Greco DC, De Santis F, Floresta A, Visconti LO, Piovaccari G, Cavallini C, Di Biase M, Masini DF, Vassanelli C, Viecca M, Cangemi DF, Pirelli S, Borghi C, Volpe M, Branzi A, Percoco DG, Severi S, Santini A, De Lorenzi E, Metra M, Zacà V, Mortara A, Tranquilino FP, Babilonia NA, Ferrolino AM, Manlutac B, Dluzniewski M, Dzielinska Z, Nowalany-Kozie E, Mazurek W, Wierzchowiecki J, Wysokinski A, Szachniewicz J, Romanowski W, Krauze-Wielicka M, Jankowski P, Berkowski P, Szelemej R, Kleinrok A, Kornacewicz-Jac Z, Vintila M, Vladoianu M, Militaru C, Dan G, Dorobantu M, Dragulescu S, Kostenko V, Vishnevsky A, Goloschekin B, Tyrenko V, Gordienko A, Kislyak O, Martsevich S, Kuchmin A, Karpov Y, Fomin I, Shvarts Y, Orlikova O, Ershova O, Berkovich O, Sitnikova M, Pakhomova I, Boldueva S, Tyurina T, Simanenkov V, Boyarkin M, Novikova N, Tereschenko S, Zadionchenko V, Shogenov Z, Gordeev I, Moiseev V, Wong R, Ong HY, Le Tan J, Goncalvesova E, Kovar F, Skalina I, Kasperova V, Hojerova S, Szentivanyi M, Stancak B, Babcak M, Kycina P, Poliacik P, Toth P, Sirotiakova J, Lopez de Sa E, Bueno MG, Selles MM, Cabrera JA, Freire RB, Gonzalez Juanatey JR, Comin J, Soriano F, Lopez A, Vicho R, Lama MG, Schaufelberger M, Brunotte R, Ullman B, Hagerman I, Cizinsky S, Cherng WJ, Yu WC, Kuo CT, Chang KC, Lai WT, Kuo JY, Ural D, Badak O, Akin M, Yigit Z, Yokusoglu M, Yilmaz M, Abaci A, Ebinc H, Perlman R, Parish D, Bergin J, Burnham K, Brown C, Lundbye J, Williams C, Eisen H, Juneman E, Joseph S, Peberdy MA, Peura J, Gupta V, Habet K, French W, Mody F, Graham S, Hazelrigg M, Chung E, Dunlap S, Nikolaidis L, Najjar S, Katz R, Murali S, Izzo JL, Callister T, Phillips R, Lippolis N, Winterton J, Meymandi S, Heilman K, Oren R, Zolty R, Brottman M, Gunawardena DR, Adams K, Barnard D, Klapholz M, and Fulmer J

Subjects
Male, medicine.medical_specialty, Cardiotonic Agents, ASTRONAUT, Diabetic Cardiomyopathies, Administration, Oral, Kaplan-Meier Estimate, Placebo, Diabete, chemistry.chemical_compound, Double-Blind Method, Fumarates, Internal medicine, Diabetes mellitus, Troponin I, Renin, Clinical endpoint, medicine, Humans, Prospective Studies, Heart Failure, Ejection fraction, business.industry, Surrogate endpoint, Aliskiren, Middle Aged, medicine.disease, Amides, Hospitalization, Endocrinology, Death, Sudden, Cardiac, Treatment Outcome, chemistry, Heart failure, Female, Cardiology and Cardiovascular Medicine, business, aliskiren
Abstract

Aims The objective of the Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT) was to determine whether alis- kiren, a direct renin inhibitor, would improve post-discharge outcomes in patients with hospitalization for heart failure (HHF) with reduced ejection fraction. Pre-specified subgroup analyses suggested potential heterogeneity in post- discharge outcomes with aliskiren in patients with and without baseline diabetes mellitus (DM). Methods and results ASTRONAUT included 953 patients without DM (aliskiren 489; placebo 464) and 662 patients with DM (aliskiren 319; placebo 343) (as reported by study investigators). Study endpoints included the first occurrence of cardiovascular death or HHF within 6 and 12 months, all-cause death within 6 and 12 months, and change from baseline in N-terminal pro-B- type natriuretic peptide (NT-proBNP) at 1, 6, and 12 months. Data regarding risk of hyperkalaemia, renal impairment, and hypotension, and changes in additional serum biomarkers were collected. The effect of aliskiren on cardiovascular death or HHF within 6 months (primary endpoint) did not significantly differ by baseline DM status (P ¼ 0.08 for interaction), but reached statistical significance at 12 months (non-DM: HR: 0.80, 95% CI: 0.64-0.99; DM: HR: 1.16, 95% CI: 0.91-1.47; P ¼ 0.03 for interaction). Risk of 12-month all-cause death with aliskiren significantly differed by the presence of baseline DM (non-DM: HR: 0.69, 95% CI: 0.50-0.94; DM: HR: 1.64, 95% CI: 1.15-2.33; P , 0.01 for interaction). Among non-diabetics, aliskiren significantly reduced NT-proBNP through 6 months and plasma troponin I and aldosterone through 12 months, as compared to placebo. Among diabetic patients, aliskiren reduced plasma troponin I and aldoster- one relative to placebo through 1 month only. There was a trend towards differing risk of post-baseline potassium ≥6 mmol/L with aliskiren by underlying DM status (non-DM: HR: 1.17, 95% CI: 0.71-1.93; DM: HR: 2.39, 95% CI: 1.30-4.42; P ¼ 0.07 for interaction). Conclusion This pre-specified subgroup analysis from the ASTRONAUT trial generates the hypothesis that the addition of aliskiren to standard HHF therapy in non-diabetic patients is generally well-tolerated and improves post-discharge outcomes and biomarker profiles. In contrast, diabetic patients receiving aliskiren appear to have worse post-discharge outcomes. Future prospective investigations are needed to confirm potential benefits of renin inhibition in a large cohort of HHF patients without DM.

Published
2013

5. C-Reactive Protein Gene Polymorphisms and the Risk of Atrial Fibrillation in a Chinese Population in Taiwan

Author

Tung, Ying-Chang, Wu, Lung-Sheng, Chen, Wei-Jan, Kuo, Chi-Tai, Wang, Chun-Li, Chang, Chi-Jen, Tsai, Hsin-Yi, Yeh, Yung-Hsin, and Hsu, Lung-An

Subjects
Mini Forum for Arrhythmia Genetics in Taiwan
Abstract

Elevated plasma C-reactive protein (CRP) levels can be used to predict an increased risk of future atrial fibrillation (AF). However, several single polynucleotide polymorphisms (SNPs) in the CRP gene affect CRP levels. This study aims to elucidate the correlation between CRP gene polymorphisms and the risk of AF among a Chinese population in Taiwan.A total of 200 patients with AF and 240 age- and gender-comparable control subjects were enrolled in this study. From these patients, five SNPs in the CRP gene were selected and genotyped.Patients with AF had significantly higher plasma CRP levels than the controls. In the total study population, the minor alleles of rs3091244 and rs1205 were significantly associated with higher CRP level (p = 0.001 and 0.045, respectively). The frequency of rs1800947 minor allele (C) was significantly higher in patients with AF than that in control subjects (12.8% and 4.6%, respectively; p0.001). On multivariate analysis, the presence of the C allele of rs1800947 was significantly and independently associated with AF after adjustment for age, gender, body mass index, hypertension, diabetes, smoking, hypercholesterolemia, coronary artery disease, concomitant medication, and CRP levels (odds ratio = 3.21; 95% confidence interval = 1.54-6.68; p = 0.01). Haplotype analysis further verified that the rs3091244C and rs1800947C bi-loci haplotype was significantly overpresented in patients with AF than in the controls.Our results suggest that the presence of the C allele of rs1800947 may indicate susceptibility to AF in a Chinese population in Taiwan.Atrial fibrillation; C-reactive protein; Polymorphism.

Published
2013

6. Revistas cardiovasculares de las sociedades nacionales europeas. Antecedentes, fundamento y declaración de objetivos del 'Club de Editores' (Grupo de trabajo de la Sociedad Europea de Cardiologia)

Author

Alfonso, Fernando, Ambrosio, Giuseppe, Pinto, Fausto J., Van Der Wall, Ernst E., Kondili, Anesti, Nibouche, Djamaleddine, Adamyan, Karlen, Huber, Kurt, Ector, Hugo, Masic, Izet, Tarnovska, Rumiana, Ivanusa, Mario, Staňek, Vladimir, Videbæk, Jørgen, Hamed, Mohamed, Laucevicius, Alexandras, Mustonen, Pirjo, Artigou, Jean Yves, Cohen, Ariel, Rogava, Mamanti, Böhm, Michael, Fleck, Eckart, Heusch, Gerd, Klawki, Rainer, Vardas, Panos, Stefanadis, Christodoulos, Tenczer, József, Chiariello, Massimo, Elias, Joseph, Benjelloun, Halima, Rødevand, Olaf, Kulakowski, Piotr, Apetrei, Edgard, Lusov, Victor A., Oganov, Rafael G., Obradovic, Velibor, Kamensky, Gabriel, Kenda, Miran F., Höglund, Christer, Lüscher, Thomas F., Lerch, René, Jokhadar, Moufid, Haouala, Habib, Sansoy, Vedat, Shumakov, Valentin, Timmis, Adam, Tajer, Carlos Daniel, Coard, Kathleen, Hajar, Rachel, Lau, Chu Pak, Chopra, H. K., Tabatabaei, Seyed Abdolhossein, Márquez, Manlio F., Samad, Abdus, Galeano, Javier, Doubell, Anton, Kuo, Chi Tai, Krittayaphong, Rungroj, Arai, Kaduo, Bacal, Fernando, and Guzmán, Luis

Subjects
Cardiology and Cardiovascular Medicine
Published
2009

8. Pravila o sukobu interesa i zahtjevi za prijavljivanjem sukoba interesa u nacionalnim kardiovaskularnim časopisima Europskog kardiološkog društva

Author

Fernando Alfonso, Adam Timmis, Fausto J. Pinto, Giuseppe Ambrosio, Hugo Ector, Piotr Kulakowski, Panos Vardas, null Editors' Network members, Loizos Antoniades, Mansoor Ahmad, Eduard Apetrei, Kaduo Arai, Jean-Yves Artigou, Michael Aschermann, Michael Böhm, Leonardo Bolognese, Raffaele Bugiardini, Ariel Cohen, Istvan Edes, Joseph Elias, Javier Galeano, Eduardo Guarda, Habib Haouala, Magda Heras, Christer Höglund, Kurt Huber, Ivan Hulin, Mario Ivanusa, Rungroj Krittayaphong, Chi-Tai Kuo, Chu-Pak Lau, Victor A. Lyusov, Germanas Marinskis, Manlio F. Márquez, Izet Masic, Luiz Felipe Pinho Moreira, Alexander Mrochek, Rafael G. Oganov, Dimitar Raev, Mamanti Rogava, Olaf Rødevand, Vedat Sansoy, Hiroaki Shimokawa, Valentin A. Shumakov, Carlos Daniel Tajer, Ernst E. van der Wall, Christodoulos Stefanadis, Jørgen Videbæk, Thomas F. Lüscher, Alfonso F, Timmis A, Pinto FJ, Ambrosio G, Ector H, Kulakowski P, Vardas P, Loizos Antoniades L, Ahmad M, Apetrei E, Arai K, Artigou JY, Aschermann M, Böhm M, Bolognese L, Bugiardini R, Cohen A, Edes I, Elias J, Galeano J, Guarda E, Haouala H, Heras M, Höglund C, Huber K, Hulin I, Ivanusa M, Krittayaphong R, Kuo CT, Lau CP, Lyusov VA, Marinskis G, Márquez MF, Masic I, Pinho-Moreira LF, Mrochek A, Oganov RG, Raev D, Rogava M, Rødevand O, Sansoy V, Shimokawa H, Shumakov VA, Tajer CD, van der Wall EE, Stefanadis C, Videbæk J, Lüscher TF, Antoniades L, Moreira LF, Christodoulos Stefanadis EE, Lüscher TF., Alfonso, Fernando, Timmis, Adam, Pinto, Fausto J., Ambrosio, Giuseppe, Ector, Hugo, Kulakowski, Piotr, Vardas, Pano, Antoniades, Loizo, Ahmad, Mansoor, Apetrei, Eduard, Arai, Kaduo, Artigou, Jean-Yve, Aschermann, Michael, Böhm, Michael, Bolognese, Leonardo, Bugiardini, Raffaele, Cohen, Ariel, Edes, Istvan, Elias, Joseph, Galeano, Javier, Guarda, Eduardo, Haouala, Habib, Heras, Magda, Höglund, Christer, Huber, Kurt, Hulin, Ivan, Ivanusa, Mario, Krittayaphong, Rungroj, Kuo, Chi-Tai, Lau, Chu-Pak, Lyusov, Victor A., Marinskis, Germana, Márquez, Manlio, Masic, Izet, Pinho Moreira, Luiz Felipe, Mrochek, Alexander, Oganov, Rafael G., Raev, Dimitar, Rogava, Mamanti, Rødevand, Olaf, Sansoy, Vedat, Shimokawa, Hiroaki, Shumakov, Valentin A., Tajer, Carlos Daniel, Van Der Wall, Ernst E., Stefanadis, Christodoulo, Videbæk, Jørgen, Lüscher, Thomas F., Repositório da Universidade de Lisboa, Editors' Network European Society of Cardiology Task Force, Sinica AC, Christer Höglund C, Fernando Alfonso, Adam Timmi, Fausto Pinto, Giuseppe Ambrosio, Hugo Ector, Piotr Kulakowski, Panos Antoniade, Mansoor Ahmad, Eduard Apetrei, Kaduo Arai, JeanYves Artigou, Michael Aschermann, Michael Bohm, Leonardo Bolognese, Raffaele Bugiardini, Ariel Cohen, Istvan Ede, Joseph Elia, Javier Galeano, Eduardo Guarda, Habib Haouala, Magda Hera, Christer Hoglund, Kurt Huber, Ivan Hulin, Mario Ivanusa, Rungroj Krittayaphong, ChiTai Kuo, ChuPak Lau, Victor Lyusov, Germanas Marinski, Manlio Mrquez, Izet Masic, Luiz Moreira, Alexander Mrochek, Rafael Oganov, Dimitar Raev, Mamanti Rogava, Olaf Rdevand, Vedat Sansoy, Hiroaki Shimokawa, Valentin Shumakov, Carlos Tajer, Ernst Wall, Christodoulos Stefanadi, Jrgen Videbk, and Thomas Luscher

Subjects
Journal, lcsh:Diseases of the circulatory (Cardiovascular) system, MEDICAL JOURNALS, CLINICAL-TRIALS, PHARMACEUTICAL-INDUSTRY, COMPETING INTERESTS, BIOMEDICAL-RESEARCH, EDITORS NETWORK, DRUG-INDUSTRY, PUBLICATION, ASSOCIATION, SPONSORSHIP, конфликт интересов, conflicts of interest, disclosure, editorial ethics, journals, Periodicals, Surveys and Questionnaires, Credibility, Conflict of interest, Publishing/ethics, Cardiology and Cardiovascular Medicine, Pharmacology (medical), Societies, Medical, раскрытие, General Environmental Science, Pharmaceutical industry, Disclosures, Editorial ethics, Journals, Medicine (all), Data Collection, Editorial ethic, General Medicine, Europe, conflict of interest, disclosure, editorial ethics, journals, Disclosure, Authorship, Cardiology, Drug Industry, Periodicals as Topic, Research Support as Topic, Conflict of Interest, Editorial Policies, medicine.medical_specialty, журналы, редакционная этика, MEDLINE, Library science, RM1-950, Truth Disclosure, Special Article, conflicts of interest, Cross-Sectional Studies, Humans, Political science, Medical, Internal medicine, medicine, Diseases of the circulatory (Cardiovascular) system, Conflict of interest, Disclosure, Editorial ethics, Journals, Closure (psychology), Drug industry, Competing interests, business.industry, lcsh:RM1-950, Conflict of interest, disclosures, editorial ethics, journals, Transparency (behavior), lcsh:Therapeutics. Pharmacology, lcsh:RC666-701, RC666-701, sukob interesa, prijavljivanje sukoba interesa, urednička etika, časopisi, General Earth and Planetary Sciences, Therapeutics. Pharmacology, cardiology, conflict of interest, Europe, interpersonal communication, medical society, publication, publishing, Societies, business
Abstract

Biomedicinski časopisi prijavljivanje sukoba interesa (COI ・prema engl. conflict of interest) koriste kako bi jamčili vjerodostojnost i transparentnost znanstvenih postupaka. Međutim,časopisi se s prijavljivanjem COI ne bave niti sistematski niti dosljedno. Nedavna zajednička nastojanja urednika su utrla put prema implementaciji jedinstvenih načina prijave COI. Ovaj dokument prža sveobuhvatni urednički stav o klasičnim problemima vezanim za COI. Raspravlja se o novim uvidima u trenutne COI smjernice i prakse nacionalnih kardiovaskularnih časopisa Europskog kardiološkog društva koji su izvedeni iz presječnog anketnog istraživanja primjenom standardiziranog upitnika., Disclosure of potential conflicts of interest (COI) is used by biomedical journals to guarantee credibility and transparency of the scientific process. COI disclosure, however, is not systematically nor consistently dealt with by journals. Recent joint editorial efforts paved the way towards the implementation of uniform vehicles for COI disclosure. This paper provides a comprehensive editorial perspective on classical COI-related issues. New insights into current COI policies and practices among European Society of Cardiology national cardiovascular journals, as derived from a cross-sectional survey using a standardised questionnaire, are discussed.

Published
2012

Catalog

Books, media, physical & digital resources
See catalog results